Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.07 USD
Change Today 0.0001 / 0.07%
Volume 8.6K
ZENO On Other Exchanges
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

zenosense inc (ZENO) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/10/14 - $0.60
52 Week Low
08/24/15 - $0.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZENOSENSE INC (ZENO)

Related News

No related news articles were found.

zenosense inc (ZENO) Related Businessweek News

No Related Businessweek News Found

zenosense inc (ZENO) Details

Zenosense, Inc., a development stage company, focuses on developing a device to detect methicillin resistant Staphylococcus aureus/Staphylococcus aureus in healthcare environments. The company was formerly known as Braeden Valley Mines, Inc. and changed its name to Zenosense, Inc. in November 2013. Zenosense, Inc. was founded in 2008 and is based in Valencia, Spain.

zenosense inc (ZENO) Top Compensated Officers

Chief Executive Officer, President, Chief Fin...
Total Annual Compensation: $75.4K
Compensation as of Fiscal Year 2014.

zenosense inc (ZENO) Key Developments

Zenosense, Inc. announced delayed 10-Q filing

On 05/15/2015, Zenosense, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Zenosense, Inc. announced delayed annual 10-K filing

On 03/30/2015, Zenosense, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device

Zenosense, Inc. announced the manufacturing of a pre-commercial prototype device to be evaluated for the detection of lung cancer in exhaled breath. Prototyping manufacture is well advanced. The work has been undertaken by the company's contracted development partner Zenon Biosystem, which is part of the Sgenia group. In line with the protocol design for an anticipated lung cancer detection trial to be held in a clinical setting, two pre-commercial Devices are currently being manufactured of the same design to ensure reproducibility of results. The completed devices are expected to be ready during the second half of the current month. The device incorporates components designed to filter out Volatile Organic Compounds not of interest in order to optimize the detection of target VOC biomarkers found in exhaled breath and associated with the incidence of lung cancer. These components and their elements include molecular sieves incorporated in complementary layered and mixed sensor structures to screen incoming VOCs, and nanometric sensing mesh to maximize the detective area. During this optimization process Zenon has developed new metal oxide materials and combinations of metal oxides that cannot be found in commercially available sensors. A complementary quartz crystal sensor employing a gas sorbent substrate has also been designed, along with a micro gas chromatography chip, for pre-detection screening. All components are of a relatively low cost consistent with the Company's intent to create cost effective products.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZENO:US $0.07 USD 0.0001

ZENO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZENO.
View Industry Companies

Industry Analysis


Industry Average

Valuation ZENO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZENOSENSE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at